- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT07896252
Phase 2b Efficacy and Safety Study of AERO-007, an Inhaled LABA+LAMA Combination for Nebulization Delivery in COPD Patients (AERODUO-2)
Randomized, Double-Blind, Placebo-Controlled, 14-Day Treatment, 2-Period Crossover Trial Evaluating the Lung Function Response After Treatment With Inhaled LABA and LAMA Monotherapies and Their Combination AERO-007 Administered Via Nebulization in Participants With Chronic Obstructive Pulmonary Disease (COPD) (AERODUO-2 Trial)
This is a phase 2b, randomized, double-blind, placebo-controlled, dose-ranging,14-day dosing, 2-period crossover study in participants with chronic obstructive pulmonary disease (COPD).
Przegląd badań
Status
Warunki
Interwencja / Leczenie
Szczegółowy opis
Combination of a long-acting beta-agonist (LABA) bronchodilator and a long-acting muscarinic antagonist (LAMA) bronchodilator is the preferred choice for initial therapy for patients with chronic obstructive pulmonary disease (COPD). Although there are currently multiple LABA+LAMA combination bronchodilators available in metered dose inhalers (MDIs), dry powder inhalers (DPI), and soft mist inhalers (SMI), a significant percentage of COPD patients, generally high risk and older patients, do not receive optimal benefit from inhalers.
Nebulized delivery provides an effective alternative where disease management is sub optimal. To date there are no approved LABA+LAMA combinations available by nebulization.
AERO-007 is a propriety inhalation solution formulation of fixed-dose combination of LABA+LAMA (indacaterol, AERO-001 and glycopyrrolate, AERO-002) for delivery in a general purpose nebulizer device. A phase 2a, single-dose, dose-ranging study of AERO-007 has been completed in participants with COPD at two dose levels (100/50 µg and 200/100 µg). AERO-007 at both low and high doses was well tolerated with robust, clinically meaningful and statistically significant bronchodilation with rapid onset of action that was sustained for 24 hours.
The objective of this phase 2b study is to determine the optimal doses of the monotherapy components of AERO-007 and to assess the safety, PK and bronchodilation profile of AERO-007 following 14 days of dosing in participants with COPD.
Typ studiów
Zapisy (Szacowany)
Faza
- Faza 2
Kontakty i lokalizacje
Kontakt w sprawie studiów
- Nazwa: Study Director Medical Director
- Numer telefonu: +1-858-750-4717
- E-mail: info@aerorxtherapeutics.com
Lokalizacje studiów
-
-
-
London, Zjednoczone Królestwo
- Rekrutacyjny
- Parexel
-
Manchester, Zjednoczone Królestwo
- Rekrutacyjny
- Medicines Evaluation Unit
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Inclusion Criteria:
-
Male or female aged 40 to 75 years, inclusive, at the time of informed consent
-
Clinical diagnosis of COPD according to the Global Initiative for Chronic Obstructive Lung Disease [GOLD] Report, 2026 for at least 12 months prior to Screening Visit 1
-
Post-bronchodilator spirometry (after 10 to 30 minutes following 4 puffs of albuterol via MDI with a spacer) at Screening Visit 2 demonstrating the following:
- FEV1 > 40 and < 80% of predicted normal (using the Global Lung Function Initiative [GLI] 2012 reference values)
- FEV1/forced vital capacity (FVC) ratio < 0.70
- ≥ 150 mL increase from pre-bronchodilator FEV1 following 4 puffs of albuterol
-
Ability to change current COPD therapy and discontinue long-acting bronchodilators, if applicable, for the duration of the trial and short-acting bronchodilators for 8 hours prior to dosing at each Treatment Visit
-
Current or former-smokers with at least 10 pack-year smoking history (eg, at least 1 pack/day for 10 years, 10 packs/day for 1 year)
-
Ability to perform reproducible spirometry according to the American Thoracic Society (ATS)/European Respiratory Society (ERS) guidelines
-
Female participants of childbearing potential must not be pregnant, breast feeding or lactating and heterosexual female participants of childbearing potential must agree to use, with their partner, a male condom plus an approved method of highly effective birth control from the time of informed consent and for 30 days following the last administered dose
-
Female participants of childbearing potential must have a negative serum or urine pregnancy test at Screening Visit 1 and a negative urine pregnancy test prior to dosing at each Treatment Visit
-
Male participants who are sexually active with a female partner of childbearing potential must use, with their partner, a male condom plus an approved method of highly effective contraception from the time of informed consent and for 30 days following the last administered dose
-
Participants must agree not to donate semen or ova/oocytes from the time of informed consent and for 30 days following the last administered dose
-
Willing and able to provide written informed consent
Exclusion Criteria:
- Current evidence or recent history of significant comorbidities; including cardiovascular disease (such as myocardial infarction, cardiac failure, uncontrolled hypertension, or life-threatening arrhythmias), uncontrolled diabetes, neurologic, psychiatric, hepatic, renal, immunological, or hematological conditions within the last 6 months prior to Screening Visit 1
- Positive serum hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibody or human immunodeficiency virus (HIV) type 1 and/or 2 antibodies at Screening Visit 1
- Lower respiratory tract infection within 6 weeks prior to Screening Visit 1
- Recent history of hospitalization due to an exacerbation of airway disease or acute worsening of COPD requiring antibiotic or systemic corticosteroid treatment within 6 months prior to Screening Visit 1
- Other respiratory disorders: Current diagnosis of predominant asthma, lung cancer, bronchiectasis, interstitial lung disease, tuberculosis, pulmonary hypertension, or other non-specific pulmonary diseases
- Prior lung volume reduction surgery or history of chest/lung irradiation
- Daily oxygen therapy for > 12 hours per day
- Body mass index >35 kg/m2
- Abnormal and clinically significant 12-lead ECG findings at Screening Visit 1
- Current or recent history of medical conditions that are contraindicated for use of an inhaled LAMA (such as urinary retention or bladder neck obstruction type symptoms, prostatic hypertrophy, or narrow-angle glaucoma) within the last 6 months prior to Screening Visit 1
- Current or recent history (previous 12 months) of excessive use or abuse of alcohol (males >21 units per week and females >14 units per week)
- Current evidence or history (within the past 2 years) of abusing legal drugs or use of illegal drugs or substances
- Donation of 450 mL of blood within 8 weeks of Screening Visit 1
- Major surgery (requiring general anaesthesia) within 6 weeks prior to Screening Visit 1, or planned surgery through the EOS Visit
- History of malignancy of any organ system, except for localized skin cancers, within 5 years prior to Screening Visit 1
- History of intolerance or hypersensitivity to any of the ingredients in the formulation for AERO-001, AERO-002, AERO-007, or other aerosol medications
- Participation in another investigational drug trial within 30 days of the last dose, 5 half-lives or twice the duration of the biological effect, whichever is longer, prior to Screening Visit 1
- History or high risk of noncompliance with trial visits and procedures or unsuitable for entry into the trial at the discretion of the Investigator
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Leczenie
- Przydział: Randomizowane
- Model interwencyjny: Przypisanie czynnikowe
- Maskowanie: Potroić
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
|---|---|
|
Komparator placebo: Placebo
|
Double-blind |
|
Eksperymentalny: Niska dawka Aero-001
|
Double-blind |
|
Eksperymentalny: Aero-001 Wysoka dawka
|
Double-blind |
|
Eksperymentalny: Niska dawka Aero-002
|
Double-blind |
|
Eksperymentalny: Aero-002 Wysoka dawka
|
Double-blind |
|
Eksperymentalny: AERO-001 medium dose
|
Double-blind |
|
Eksperymentalny: AERO-002 medium dose
|
Double-blind |
|
Eksperymentalny: AERO-007
|
Double-blind |
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Ramy czasowe |
|---|---|
|
Bronchodilation - FEV1
Ramy czasowe: Change from baseline in FEV1 at 24 hours post-dose on Days 1 and 14
|
Change from baseline in FEV1 at 24 hours post-dose on Days 1 and 14
|
|
Bronchodilation - FEV AUC
Ramy czasowe: Change from baseline in FEV1 AUC(0-24 hours) on Days 1 and 14
|
Change from baseline in FEV1 AUC(0-24 hours) on Days 1 and 14
|
|
Bronchodilation - Peak FEV1
Ramy czasowe: Peak change in FEV1 within 4 hours post-dose on Days 1 and 14
|
Peak change in FEV1 within 4 hours post-dose on Days 1 and 14
|
|
Bronchodilation - time to onset of FEV1 >100mL
Ramy czasowe: Change in FEV1 >100mL from pre-dose on Days 1 and 14
|
Change in FEV1 >100mL from pre-dose on Days 1 and 14
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Pharmacokinetics - Cmax
Ramy czasowe: 0-24 hours on Days 1 and 14
|
Cmax (maximum plasma concentration) |
0-24 hours on Days 1 and 14
|
|
Pharmacokinetics - AUC
Ramy czasowe: AUC(0-6 hours) on Days 1 and 14
|
AUC (area under the plasma concentration) |
AUC(0-6 hours) on Days 1 and 14
|
|
Pharmacokinetics - Tmax
Ramy czasowe: Tmax on Days 1 and 14
|
Tmax (time to maximum concentration) |
Tmax on Days 1 and 14
|
|
Treatment-emergent adverse events (TEAEs)
Ramy czasowe: Up to approximately Day 14
|
Number of participants with TEAEs |
Up to approximately Day 14
|
|
Blood Pressure
Ramy czasowe: Up to approximately Day 14
|
Number of participants with markedly abnormal changes in Blood Pressure |
Up to approximately Day 14
|
|
Heart Rate
Ramy czasowe: Up to approximately Day 14
|
Number of participants with markedly abnormal changes in Heart Rate |
Up to approximately Day 14
|
|
12-lead ECG - QT Interval corrected for Heart Rate Using Fridericia's Formula (QTcF)
Ramy czasowe: Up to approximately Day 14
|
Number of participants with markedly abnormal changes in QTcF |
Up to approximately Day 14
|
|
Clinical laboratory - Hematology
Ramy czasowe: Up to approximately Day 14
|
Number of participants with markedly abnormal changes in hematology parameters |
Up to approximately Day 14
|
|
Clinical laboratory - Blood Chemistry
Ramy czasowe: Up to approximately Day 14
|
Number of participants with markedly abnormal changes in blood chemistry parameters |
Up to approximately Day 14
|
Współpracownicy i badacze
Sponsor
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Rzeczywisty)
Zakończenie podstawowe (Szacowany)
Ukończenie studiów (Szacowany)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
- Bezpieczeństwo
- POChP
- Skuteczność
- Farmakokinetyka
- Kontrolowane placebo
- Randomizowane
- Podwójnie ślepe
- Inhalacja
- Nebulizacja
- Faza 2b
- FEV1
- Indakaterol
- LABA
- LAMA
- Rozszerzenie oskrzeli
- Zakres dawek
- LABA+LAMA
- General purpose nebulizer
- 2-period crossover
- Glaycopyrrolate
- AeroRx
- AERO-007
- indacaterol+glycopyrrolate
Dodatkowe istotne warunki MeSH
Inne numery identyfikacyjne badania
- AERO-007-02
- 2026-527150-39 (Numer EudraCT)
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .